TheraDerm
PreclinicalSmall molecule
TheraDerm is one of 4 small molecule programs targeting Hypopituitarism. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Hypopituitarism
#DrugCompanyPhaseTrials
1Genotropin
EMD SeronoPhase 3
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Capromorelin
UUniversity of Aarhus
Preclinical
TheraDerm
MMassachusetts General Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TheraDerm. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMassachusetts General Hospital